Calcifediol Treatment and Hospital Mortality Due to COVID-19 : A Cohort Study
CONTEXT: Calcifediol has been proposed as a potential treatment for COVID-19 patients.
OBJECTIVE: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19.
DESIGN: Retrospective, multicenter, open, non-randomized cohort study.
SETTINGS: Hospitalized care.
PATIENTS: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain.
INTERVENTION: Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not.
MAIN OUTCOME MEASURE: In-hospital mortality during the first 30 days after admission.
RESULTS: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80).
CONCLUSION: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Nutrients - 13(2021), 6 vom: 21. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alcala-Diaz, Juan F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 08.06.2021 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/nu13061760 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326126686 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326126686 | ||
| 003 | DE-627 | ||
| 005 | 20231225193925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/nu13061760 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326126686 | ||
| 035 | |a (NLM)34064175 | ||
| 035 | |a (PII)1760 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alcala-Diaz, Juan F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Calcifediol Treatment and Hospital Mortality Due to COVID-19 |b A Cohort Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Calcifediol has been proposed as a potential treatment for COVID-19 patients | ||
| 520 | |a OBJECTIVE: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19 | ||
| 520 | |a DESIGN: Retrospective, multicenter, open, non-randomized cohort study | ||
| 520 | |a SETTINGS: Hospitalized care | ||
| 520 | |a PATIENTS: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain | ||
| 520 | |a INTERVENTION: Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not | ||
| 520 | |a MAIN OUTCOME MEASURE: In-hospital mortality during the first 30 days after admission | ||
| 520 | |a RESULTS: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80) | ||
| 520 | |a CONCLUSION: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 drug treatment | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a calcifediol | |
| 650 | 4 | |a vitamin D | |
| 650 | 7 | |a Calcifediol |2 NLM | |
| 650 | 7 | |a P6YZ13C99Q |2 NLM | |
| 700 | 1 | |a Limia-Perez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez-Huelgas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Escalante, Maria D |e verfasserin |4 aut | |
| 700 | 1 | |a Cortes-Rodriguez, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Zambrana-Garcia, Jose L |e verfasserin |4 aut | |
| 700 | 1 | |a Entrenas-Castillo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Caballero, Ana I |e verfasserin |4 aut | |
| 700 | 1 | |a López-Carmona, Maria D |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Alegria, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano Rodríguez-Mancheño, Aquiles |e verfasserin |4 aut | |
| 700 | 1 | |a Arenas-de Larriva, Maria Del Sol |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Belmonte, Luis M |e verfasserin |4 aut | |
| 700 | 1 | |a Jungreis, Irwin |e verfasserin |4 aut | |
| 700 | 1 | |a Bouillon, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Quesada-Gomez, Jose Manual |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Miranda, Jose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nutrients |d 2009 |g 13(2021), 6 vom: 21. Mai |w (DE-627)NLM206140738 |x 2072-6643 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:6 |g day:21 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/nu13061760 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 6 |b 21 |c 05 | ||